CLGN revenueFY2025$2.37M
- FY YoY
- +360.4%
- 5Y CAGR
- -17.3%
CLGN revenue was $2.37M for fiscal 2025 (ended Dec 31, 2025), up 360.4% from fiscal 2024. Compound annual growth was -17.3% over 5 years. It rose in 5 of the last 8 fiscal years.
CollPlant Biotechnologies Ltd (CLGN) financials
For fiscal 2025 (ended Dec 31, 2025), CollPlant Biotechnologies Ltd reported $2.37M of revenue and -$11.49M of net income.
- Revenue, FY2025
- $2.37M
- Revenue growth, YoY
- +360.4%
- Net income, FY2025
- -$11.49M
- Net margin
- -484.6%
- Free cash flow, FY2025
- -$9.45M
- EPS, diluted, FY2025
- -$0.94
- Cash
- $5.59M
- P/S
- 5.15
- Market cap
- $12.2M
FY2017FY2025
FY2017FY2025
FY2017FY2025
CLGN revenue and earnings growth
CLGN net incomeFY2025-$11.49M
CLGN net income was -$11.49M for fiscal 2025 (ended Dec 31, 2025), compared with -$16.61M in fiscal 2024.
CLGN EPSFY2025-$0.94
CLGN diluted EPS was -$0.94 for fiscal 2025 (ended Dec 31, 2025), compared with -$1.45 in fiscal 2024.
CLGN free cash flowFY2025-$9.45M
CLGN free cash flow was -$9.45M for fiscal 2025 (ended Dec 31, 2025), compared with -$14.58M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.37M | $515.0K | $10.96M | $299.0K | $15.64M | $6.14M | $2.32M | $5.01M | $463.0K |
| Cost of revenue | $835.0K | $1.63M | $1.99M | $400.0K | $2.00M | $3.00M | $1.88M | $1.66M | $48.0K |
| Gross profit | $1.54M | -$1.11M | $8.97M | -$101.0K | $13.64M | $3.13M | $439.0K | $3.35M | $415.0K |
| Research and development | $8.19M | $10.52M | $10.48M | $10.26M | $7.63M | $4.07M | $4.41M | $3.88M | $584.0K |
| Selling, general and admin | $4.83M | $5.63M | $6.00M | $6.74M | $5.94M | $4.67M | $3.66M | $3.72M | $2.47M |
| Operating income | -$11.48M | -$17.25M | -$7.51M | -$17.10M | $65.0K | -$5.60M | -$7.63M | -$4.25M | -$5.96M |
| Interest expense | - | - | - | - | - | - | $3.30M | $2.18M | $47.0K |
| Income tax | - | $45.99M | $59.99M | - | - | - | - | - | - |
| Net income | -$11.49M | -$16.61M | -$7.02M | -$16.93M | $237.0K | -$5.77M | -$11.16M | -$6.25M | -$6.05M |
| EPS, basic | -$0.94 | -$1.45 | -$0.62 | -$1.53 | $0.02 | -$0.84 | -$2.23 | $1.43 | - |
| EPS, diluted | -$0.94 | -$1.45 | -$0.62 | -$1.53 | $0.02 | -$0.84 | -$2.23 | $1.43 | - |
| Diluted shares | 12.2M | 11.5M | 11.4M | 11.0M | 12.0M | 6.9M | 5.0M | 4.4M | 2.7M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $5.59M | $11.91M | $26.67M | $29.86M | $13.37M | $3.53M | $3.79M | $5.66M | $5.28M |
| Receivables | $1.0K | $150.0K | - | $9.0K | $270.0K | $830.0K | $79.0K | - | - |
| Inventory | $573.0K | $440.0K | $714.0K | $1.43M | $1.08M | $1.26M | $888.0K | $814.0K | $202.0K |
| Current assets | $6.75M | $13.18M | $28.02M | $31.66M | $45.09M | $5.68M | $5.04M | $7.17M | $6.46M |
| Total assets | $10.79M | $18.71M | $34.13M | $37.77M | $51.22M | $10.84M | $10.75M | $8.75M | $8.09M |
| Current liabilities | $2.67M | $2.97M | $3.25M | $3.10M | $3.01M | $3.39M | $3.46M | $2.23M | $1.42M |
| Short-term debt | - | - | - | $321.0K | $219.0K | - | - | - | - |
| Total debt | - | - | - | - | $30.0K | $11.0K | $63.0K | - | $2.00M |
| Total liabilities | $4.70M | $5.25M | $5.79M | $5.49M | $6.10M | $6.36M | $6.66M | $3.33M | $5.47M |
| Shareholders' equity | $6.08M | $13.46M | $28.34M | $32.28M | $45.12M | $4.48M | $4.09M | $5.42M | $5.17M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.42M | -$14.09M | -$2.76M | -$13.70M | $2.50M | -$4.45M | -$5.70M | -$1.22M | -$4.97M |
| Capital expenditures | $28.0K | $483.0K | $954.0K | $1.27M | $1.43M | $437.0K | $1.49M | $832.0K | $127.0K |
| Free cash flow | -$9.45M | -$14.58M | -$3.72M | -$14.97M | $1.07M | -$4.89M | -$7.19M | -$2.05M | -$5.09M |
| Investing cash flow | -$27.0K | -$539.0K | -$1.16M | $28.92M | -$31.56M | -$519.0K | -$1.46M | -$832.0K | -$127.0K |
| Financing cash flow | $3.10M | $9.0K | $1.11M | $1.87M | $38.76M | $4.46M | $5.41M | $2.75M | $9.11M |
| Stock-based compensation | $999.0K | $1.72M | $1.94M | $2.17M | $1.60M | - | $1.13M | $1.43M | $956.0K |
| Depreciation and amortization | $912.0K | $1.04M | $1.10M | $1.08M | $773.0K | $660.0K | $539.0K | $342.0K | $230.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 360.4% | -95.3% | 3565.2% | -98.1% | 154.9% | 164.8% | -53.8% | 982.9% | - |
| Gross margin | 64.8% | -215.5% | 81.8% | -33.8% | 87.2% | 51.1% | 18.9% | 66.9% | 89.6% |
| Operating margin | -484.3% | -3349.7% | -68.5% | -5718.1% | 0.4% | -91.2% | -329.2% | -84.7% | -1286.6% |
| Net margin | -484.6% | -3225.0% | -64.0% | -5660.5% | 1.5% | -94.1% | -481.6% | -124.6% | -1306.9% |
| Free cash flow margin | -398.4% | -2830.3% | -33.9% | -5007.4% | 6.9% | -79.6% | -310.4% | -40.9% | -1100.0% |
| Return on equity | -188.9% | -123.3% | -24.8% | -52.4% | 0.5% | -129.0% | -273.1% | -115.3% | -117.0% |
| Return on assets | -106.5% | -88.8% | -20.6% | -44.8% | 0.5% | -53.3% | -103.8% | -71.4% | -74.8% |
| Current ratio | 2.53 | 4.44 | 8.62 | 10.20 | 14.96 | 1.68 | 1.46 | 3.21 | 4.56 |
| Debt to equity | - | - | - | - | 0.00 | 0.00 | 0.02 | - | 0.39 |
Source: XBRL data CollPlant Biotechnologies Ltd files with the SEC, latest filing dated Mar 26, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
CLGN peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CLGN | $2.37M | +360.4% | -$11.49M | -484.6% | $12.2M |
| ISRG | $11.58B | +20.5% | $2.96B | 25.5% | $156.96B |
| EW | $6.67B | +13.4% | $1.02B | 15.3% | $58.73B |
| STE | $6.17B | +8.1% | $826.90M | 13.4% | $24.60B |
| ZBH | $8.57B | +7.0% | $767.30M | 9.0% | $19.98B |
| MAS | $7.67B | +0.9% | $926.00M | 12.1% | $15.85B |
| SNN | $6.16B | +6.1% | $625.00M | 10.1% | $13.04B |
| ALGN | $4.16B | +4.4% | $491.87M | 11.8% | $11.70B |
| AIT | $5.06B | +8.5% | $424.12M | 8.4% | $10.35B |
CLGN FAQ
9 questionsWhat is CLGN revenue?
CollPlant Biotechnologies Ltd (CLGN) reported $2.37M of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 360.4% from the year before.Is CLGN profitable?
No. CollPlant Biotechnologies Ltd reported a net loss of $11.49M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does CLGN have?
CollPlant Biotechnologies Ltd reported $5.59M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is CLGN revenue growing?
CollPlant Biotechnologies Ltd's revenue changed +360.4% in fiscal 2025, to $2.37M. Its compound annual growth rate was -17.3% over 5 years.What is CLGN gross margin?
CollPlant Biotechnologies Ltd's gross profit was $1.54M on $2.37M of revenue for fiscal 2025 (ended Dec 31, 2025), a gross margin of 64.8%.What is CLGN free cash flow?
CollPlant Biotechnologies Ltd generated -$9.45M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$9.42M less capital expenditures.What is CLGN earnings per share?
Diluted earnings per share were -$0.94 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did CLGN last report financial results?
The latest statements here come from CollPlant Biotechnologies Ltd's 20-F filed on Mar 26, 2026, covering the period ended Dec 31, 2025.Where does this CLGN financial data come from?
Quantisnow builds these statements from the structured XBRL data CollPlant Biotechnologies Ltd files with the SEC. It is provided for information only and is not investment advice.